Skip to main content

Table 1 Clinical and echocardiographic findings of Group I patients (n = 64) in the two treatment groups

From: Evaluating the effectiveness of rosuvastatin in preventing the progression of diastolic dysfunction in aortic stenosis: A substudy of the aortic stenosis progression observation measuring effects of rosuvastatin (ASTRONOMER) study

Characteristics

Placebo (n = 37)

 

Rosuvastatin (n = 27)

 

p value

 

Baseline

Follow-up

Baseline

Follow-up

 

Age, y

56 ± 13

 

51 ± 11

 

0.17

Hemodynamics

     

HR (bpm)

70 ± 8

70 ± 11

70 ± 8

68 ± 10

0.82

SBP (mm Hg)

130 ± 17

131 ± 13

131 ± 20

132 ± 17

0.76

DBP (mm Hg)

77 ± 10

77 ± 13

76 ± 9

74 ± 11

0.79

Aortic Valve Parameters

     

AVA (cm2)

1.9 ± 0.7

1.6 ± 0.7*

1.9 ± 0.6

1.6 ± 0.6†

0.62

AV peak velocity (m/s)

2.8 ± 0.1

3.3 ± 0.7*

2.7 ± 0.2

3.1 ± 0.5†

0.57

AV peak gradient (mm Hg)

31 ± 3

42 ± 11*

32 ± 3

43 ± 12†

0.60

AV mean gradient (mm Hg)

17 ± 2

31 ± 3*

17 ± 2

30 ± 4†

0.58

Left Heart Dimensions

     

IVS (mm)

11 ± 2

11 ± 2

11 ± 2

11 ± 2

0.94

PWT (mm)

10 ± 2

11 ± 2

10 ± 2

10 ± 2

0.76

LA (mm)

37 ± 6

37 ± 6

36 ± 6

37 ± 7

0.78

LVEDD (mm)

49 ± 5

49 ± 7

49 ± 7

49 ± 7

0.81

LVESD (mm)

29 ± 4

29 ± 7

29 ± 6

29 ± 6

0.84

LV mass/BSA (g/m2)

     

   Men

95 ± 24

93 ± 23

94 ± 28

95 ± 23

0.61

   Women

85 ± 19

87 ± 25

84 ± 24

86 ± 19

0.69

EF (%)

65 ± 6

67 ± 4

65 ± 6

68 ± 9

0.58

Conventional Diastolic Parameters

     

Mitral E velocity (cm/sec)

84 ± 19

88 ± 23

82 ± 20

89 ± 21

0.59

Mitral A velocity (cm/sec)

74 ± 18

76 ± 18

73 ± 25

75 ± 25

0.64

E/A ratio

1.2 ± 0.4

1.1 ± 0.3

1.1 ± 0.4

1.2 ± 0.5

0.71

Tissue Doppler Imaging

     

Lateral S'

8.4 ± 3.2

8.3 ± 1.8

8.5 ± 2.3

8.4 ± 2.1

0.75

Lateral E'

10.2 ± 4.2

8.0 ± 3.2*

10.5 ± 3.5

8.2 ± 3.1†

0.66

Lateral A'

9.2 ± 3.6

9.4 ± 2.8

9.1 ± 2.4

9.4 ± 3.0

0.56

E/E' (lateral)

8 ± 4

11 ± 3*

8 ± 3

11 ± 4†

0.43

  1. Values are mean ± SD (percentage). y, years; SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; bpm, beats per minute; AVA, aortic valve area; AV, aortic valve; IVS, interventricular septum; PWT, posterior wall thickness; LA; left atrium diameter in anterior-posterior dimension; LVEDD, left ventricular end diastolic diameter; LVESD, left ventricular end systolic diameter; LV, left ventricular; BSA, body surface area; EF, ejection fraction; S', systolic annular velocity; E', early diastolic annular velocity; A', late diastolic annular velocity. p < 0.05* was considered significant comparing baseline and follow-up values within the placebo arm. p < 0.05† was considered significant comparing baseline and follow-up values within the rosuvastatin arm. Overall p values are listed for the difference of baseline and follow-up measurements comparing placebo vs. rosuvastatin, with p < 0.05‡ considered significant.